AIM： To assess the incidence of MLH1 （the human MutL homologue） and MSH2 （the human MutS homologue） protein expression in Turkish patients with sporadic colorectal cancers and to compare their survival and clinic...AIM： To assess the incidence of MLH1 （the human MutL homologue） and MSH2 （the human MutS homologue） protein expression in Turkish patients with sporadic colorectal cancers and to compare their survival and clinicopathological features. METHODS： We validated the tissue microarray technology in 77 colorectal carcinomas by analyzing the immunohistochemical expression of proteins involved in two main pathways of colorectal carcinogenesis： p53 protein for loss of heterozygosity tumors; MLH1 and MSH2 proteins for microsatellite instability （MSI）. RESULTS： Our analysis showed that 29 （39.2%） had loss of MLH1 expression, 5 （6.8%） had loss of MSH2 expression and 2 cases had loss of expression of both proteins. We found that 60% of MSH2-negative tumors were located in the right side of the colon; all MSH2-negative cases were women. In addition, the loss of MSH2 expression was correlated with low p53 expression. Neither MLH1 nor MSH2 expressions were associated with prognosis, although there seemed a tendency of longer survival （71.7 ± 8.65 mo vs 47.08± 5.26 too） for the patients with MLHl-negative versus MLHl-positive carcinomas. There were not significant differences in overall and recurrence-free survival among MLH1/MSH2-positive and -negative cases.CONCLUSION： Our data supports that Turkish patients with MLH1- and MSH2-defective tumors have some distinct features from each other. Although prognostic importance remains controversial, immunohistochemical analysis of mismatch repair genes may be used as a routine histopathological examination of sporadic colorectal carcinomas.展开更多
基金the Research Foundation of Istanbul University,No T-493/25062004
文摘AIM： To assess the incidence of MLH1 （the human MutL homologue） and MSH2 （the human MutS homologue） protein expression in Turkish patients with sporadic colorectal cancers and to compare their survival and clinicopathological features. METHODS： We validated the tissue microarray technology in 77 colorectal carcinomas by analyzing the immunohistochemical expression of proteins involved in two main pathways of colorectal carcinogenesis： p53 protein for loss of heterozygosity tumors; MLH1 and MSH2 proteins for microsatellite instability （MSI）. RESULTS： Our analysis showed that 29 （39.2%） had loss of MLH1 expression, 5 （6.8%） had loss of MSH2 expression and 2 cases had loss of expression of both proteins. We found that 60% of MSH2-negative tumors were located in the right side of the colon; all MSH2-negative cases were women. In addition, the loss of MSH2 expression was correlated with low p53 expression. Neither MLH1 nor MSH2 expressions were associated with prognosis, although there seemed a tendency of longer survival （71.7 ± 8.65 mo vs 47.08± 5.26 too） for the patients with MLHl-negative versus MLHl-positive carcinomas. There were not significant differences in overall and recurrence-free survival among MLH1/MSH2-positive and -negative cases.CONCLUSION： Our data supports that Turkish patients with MLH1- and MSH2-defective tumors have some distinct features from each other. Although prognostic importance remains controversial, immunohistochemical analysis of mismatch repair genes may be used as a routine histopathological examination of sporadic colorectal carcinomas.
